Transkaryotic says Replagal panel not likely

TKTX said it does not expect an FDA advisory committee to review its BLA for Replagal agalsidase alfa enzyme replacement therapy for Fabry disease. On Wednesday, Genzyme (GENZ) said it has been inform...